This review is written from the perspective of the pediatric clinician involved in the care of premature infants at risk for pulmonary hypertension. The main objective is to better inform the clinician in the diagnosis and treatment of pulmonary hypertension in premature infants by reviewing the available relevant literature and focusing on the areas for which there is the greatest need for continued research.
INTRODUCTION
Infants born prematurely are at risk of developing bronchopulmonary dysplasia (BPD). Since its original description in the late 1960's, the definition of BPD has changed dramatically from a description of stiff surfactant deficient lungs that were damaged by conventional ventilators [1] to a more modern definition that describes lung growth arrest and decreased alveolarization [2, 3] . Many medical advances have led to this transition in the description of BPD and concurrent with this change a greater number of premature infants are surviving to hospital discharge, though not without significant morbidity [4] .
Pulmonary hypertension is increasingly recognized as a cause of significant morbidity and even mortality in premature infants. Infants with BPD are at even greater risk for pulmonary hypertension [5 & ,6 & ]. In addition, recent data suggest that detection of early pulmonary hypertension is a predictor for greater severity of BPD [7 & ]. A correlation between the diagnosis of BPD and pulmonary hypertension is not surprising, given that alveolarization during lung growth requires pulmonary vascular development [8] . Consequently, understanding the pathophysiology of pulmonary hypertension in the BPD population involves an understanding of the interactions of these two processes, as well as how other factors such as inflammation can influence these interactions [9] .
Recent guidelines now recommend that all infants with BPD should be screened with an echocardiogram for pulmonary hypertension [10 BPD-associated pulmonary hypertension (BPD-PH). Current practice focuses on minimizing secondary insults to the developing lungs as well as maximizing nutrition to support optimal growth of the infant [8] . Pulmonary hypertension-specific medications are used in this infant population, but there is little evidence to guide best practice in medication, selection, and dosing [11] .
In this review, we discuss the current understanding of pulmonary hypertension in the BPD population. By highlighting the current understanding of pathophysiology, epidemiology, diagnostics, and treatment we also hope to highlight the areas where more research is desperately needed to improve the health of this very vulnerable population.
PATHOPHYSIOLOGY OF PULMONARY HYPERTENSION IN BRONCHOPULMONARY DYSPLASIA
The understanding of the pathophysiology of BPD-PH begins with an understanding of how the pulmonary vasculature develops and functions in utero. Although there are still many questions to answer, it is widely accepted that the pulmonary blood vessels develop alongside the airways and throughout development the lung endoderm and vasculature mesoderm are interacting through molecular pathways [9, 12, 13] . Vascular endothelial growth factor (VEGF) is very important for signaling of vascular growth and endothelial cell proliferation [14, 15] , and this endothelial cell signaling closely interacts with signaling for lung development. Fibroblast growth factors are important regulators of lung development [16] and some of these growth factors are involved with VEGF signaling in capillary development in the distal lung [17] . In summary, pulmonary growth and vascular development occurs together through a complex interaction of multiple signaling cascades.
During the in-utero process of distal lung growth and vascular development, the pulmonary vascular system is in a state of high vascular resistance. This physiological state facilitates the diverting of the majority of pulmonary blood flow away from the lungs to other organs of the developing fetus. However, after birth, with establishment of an air-liquid interface, ventilation, and an increase in oxygen tension, pulmonary blood flow increases from eight to 10-fold and pulmonary arterial pressure decreases by half within the few days of life [18] . However, in the context of prematurity, alveolarization is incomplete and pulmonary microvascular development is arrested [11, 19] . Growth arrest results in decreased cross-sectional area for blood flow and increased pulmonary vascular resistance (PVR). In the context of increased PVR, vasoreactivity is also altered, vascular remodeling occurs, and metabolic function is impaired [8, 20] . Prematurity with arrest of pulmonary vascular growth can be further complicated by prenatal insults to the developing pulmonary vasculature.
Causes of prenatal injury include intrauterine growth restriction, infection with resulting inflammation, and conditions that decrease placental blood flow, such as preeclampsia [10 && ]. A retrospective cohort study of 138 infants less than 28 weeks gestational age, demonstrated that a low birth weight for gestational age was an important predictor of BPD-PH in infants with moderate-to-severe BPD [21] . A retrospective cohort study of 98 preterm infants with BPD found that oligohydramnios was a specific risk factor for BPD-PH in preterm infants with moderate or severe BPD [22] . Thus, oligohydramnios may be a risk factor for pulmonary hypertension owing to alterations in alveolarization, lung development, and, as a consequence, compromised pulmonary vascular development. Alterations in placental blood flow, such as in preeclampsia, can also affect fetal growth, which can increase the risk for pulmonary hypertension in premature infants as already discussed. In addition, alterations in placental blood flow can alter developmental vascular signaling as has been suggested in some animal models [23, 24] . These studies serve to highlight some of the possible risk factors for the development of pulmonary hypertension in the premature infant
KEY POINTS
The pathophysiology of pulmonary hypertension in the premature infant involves decreased lung growth and alveolarization with concurrent decreased pulmonary vascular growth that results in decreased pulmonary capillary surface area.
BPD is associated with the development of pulmonary hypertension in the premature infant population.
In addition to BPD, low birth weight and causes of increased inflammation have been associated with the development of pulmonary hypertension.
It is now recommended that all infants with BPD have an echocardiogram to evaluate for evidence of pulmonary hypertension at 36 weeks corrected gestational age.
There is need for greater evidence regarding best treatment practices, but routine care starts with minimizing secondary insults to the developing lungs and promotion of optimal growth. population and may represent considerations for pulmonary hypertension risk stratification and potential therapeutic targets.
Postnatal factors implicated as causes for increasing a premature infant's risk of developing pulmonary hypertension include poor growth, infection, mechanical ventilation, and altered hemodynamics as with a patent ductus arteriosus [8] . Inflammation, whether from infection or other exposures, has been implicated in both animal models and human observational studies as a risk factor for the development of pulmonary hypertension. More specifically, animal models have shown that reactive oxygen species alter hemodynamics by decreasing normal pulmonary artery relaxation to vasodilators and causing vascular remodeling [25, 26] . In addition, mechanical ventilation and oxygen therapy can also affect angiogenic signaling and gene expression [20] and increase reactive oxygen species generation. Altered hemodynamics, including systemic to pulmonary vasculature shunting, can result in pulmonary vascular stress that can lead to vascular remodeling and increased risk of pulmonary hypertension [27, 28] .
In summary, lung growth and pulmonary vascular development occur concomitantly through interacting signaling cascades such that alterations in one process can often alter the other. Multiple factors, both before and after birth, can affect lung and pulmonary vascular development as represented in Fig. 1 . These observations provide opportunities for risk-stratification as well as points for therapeutic intervention.
EPIDEMIOLOGY AND PROGNOSIS OF PULMONARY HYPERTENSION IN THE PREMATURE INFANT POPULATION
As a result of advances in neonatal care, extremely premature infants (gestational age 22-28 weeks) are surviving to hospital discharge more than in the past [4] . Although survival is accompanied by multiple challenges, most of these infants do not develop pulmonary hypertension. However, for those who develop pulmonary hypertension the morbidity and mortality is high. Consequently, efforts are underway to better elucidate the epidemiology of pulmonary hypertension in premature infants so as to identify preventable risk factors that predispose the few to long-term significant pulmonary hypertension.
Pulmonary hypertension complicates BPD in 10-30% of cases and BPD accounts for about 5% of childhood pulmonary hypertension [ For most infants, symptoms of pulmonary hypertension resolve within the first year of life as respiratory symptoms concurrently improve. However, this is not the case for all infants and there is evidence that the presence of pulmonary hypertension does increase the risk of mortality [30] . A recent review of a Danish cohort found that 82% of premature infants with pulmonary hypertension had moderate/severe BPD [6 & ], and a similar incidence was recently reported in a cohort in the United States [31] . Thus, there is recognition that BPD is a risk factor for the development of pulmonary hypertension in the premature infant population; and pulmonary hypertension risk appears to increase with increasing BPD severity.
However, determining the true incidence of pulmonary hypertension in the context of BPD is confounded by variability in the definition of BPD [32] . In addition, some premature infants develop pulmonary hypertension even in the absence of BPD. Regardless of BPD status, increasing days on mechanical ventilation and a greater length of stay have been associated with pulmonary hypertension in the premature infant population [6 & ]. Therefore, in addition to the recent guidelines [10 && ] suggesting evaluation for pulmonary hypertension in the BPD population, it may be reasonable to consider screening a broader cohort of premature infants with other risk factors.
EVALUATION OF PULMONARY HYPERTENSION IN THE PREMATURE INFANT POPULATION
Cardiac catheterization is considered the gold standard for the diagnosis of pulmonary hypertension, which is typically defined as a mean pulmonary artery pressure over 25 mmHg in children and adults regardless of age. Furthermore, pediatric pulmonary hypertensive vascular disease has been used as a term to identify children with pulmonary hypertension accompanied by elevated PVR (PVR>3.0 WU/ m 2 for biventricular circulations), which is the type of pulmonary hypertension typically seen in premature infants [33] . But in the vulnerable premature infant population with little pulmonary reserve, the risks of cardiac catheterization often force clinicians to rely on noninvasive metrics of pulmonary hypertension such as the transthoracic echocardiogram. Echocardiograms provide a tremendous amount of diagnostic information regarding pulmonary hypertension, but there is a significant need for standardization of parameters in the BPD population [34 & ]. The standard evaluation of pulmonary hypertension by echocardiogram focuses on parameters related to the right ventricle and, when present, the tricuspid regurgitant jet velocity (TRJV) is a useful parameter to estimate the right ventricular systolic pressure [35] . However, in many cases an accurate estimate of right ventricular systolic pressure is not always possible as tricuspid regurgitation may be undetectable or TRJV may be incomplete and, thus, alternative parameters are employed [34 & ]. Consequently, there is a need for other echocardiographic parameters. Nagiub and colleagues [34 & ] recently reviewed the literature and proposed an echocardiogram screening protocol for infants with BPD. Overall, the proposed protocol suggests using parameters such as patent ductus arteriosus blood flow, left pulmonary artery flow analysis, and septal geometry when TRJV cannot be accurately estimated.
In addition, there are also recent data that suggest that echocardiogram evidence of pulmonary hypertension at 7 days of life predicts the development of BPD with late pulmonary hypertension in preterm infants [7 & ]. One of the implications of this report is that it may be possible to predict the later development of BPD-PH with early in life echocardiograms [36] . This report underscores the need for screening for pulmonary hypertension both early and late in the neonatal ICU course, as lung growth and vascular development are interdependent from the beginning of development.
There is, therefore, a wealth of information accessible by echocardiogram. In pediatric populations, especially the BPD population, the biggest issue is lack of standardization of these parameters. Because cardiac catheterization is not routinely performed in the BPD population many of these echocardiogram parameters are necessary proxies for pulmonary hypertension. However, the fidelity between cardiac catheterization and echocardiogram findings is often less than optimal [37] . Furthermore, there are technical challenges to performing echocardiograms in these small premature infants and there is often considerable interobserver variability. Overall, there is a need for greater standardization of echocardiogram parameters in the BPD population.
Other testing can be used to help risk stratify infants with concerns for pulmonary hypertension, including serum B-type natriuretic peptide (BNP) levels, which is elevated in individuals with conditions of cardiac strain. BNP levels are elevated in children and adults with pulmonary hypertension. In the context of premature infants with BPD-PH, elevated BNP level is associated with an increased risk of mortality [38] . However, an elevated BNP level is relatively nonspecific and may have the greatest utility as a laboratory parameter to follow longitudinally. Cardiac MRI represents another promising noninvasive modality for the diagnosis of pulmonary hypertension [39] , but this testing is also expensive, time consuming, and in the BPD population frequently requires sedation, which is not without risk. Again, in this very vulnerable population it seems most appropriate to continue to focus efforts on improving and standardizing noninvasive assessments of pulmonary hypertension.
TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION IN THE BRONCHOPULMONARY DYSPLASIA POPULATION
Rather than pharmacologic interventions, the first step in the management and treatment of pulmonary hypertension in the BPD population is attention to interventions to protect the developing lungs from future insults and supporting optimal lung growth. The pathophysiology of pulmonary hypertension in infants with BPD relates to decreased lung growth, specifically alveolarization, and arrested pulmonary vascular development, which ultimately leads to decreased pulmonary capillary surface area and consequently pulmonary hypertension. However, we know that alveolarization is an active process that continues beyond the first year of life [3] . When alveolarization improves so does pulmonary capillary development and consequently promoting optimal lung growth is a key component of pulmonary hypertension management in the BPD population. A significant part of this includes promoting optimal nutrition and monitoring for adequate weight gain. As already discussed, infants that are small for gestational age are at increased risk for the development of pulmonary hypertension and, thus, optimal lung growth is of extreme importance in these very vulnerable infants.
In addition to promoting growth, protecting the developing lungs from secondary insults that can worsen pulmonary hypertension is also important. Clinical situations such as gastroesophageal reflux and dysphagia with aspiration can worsen lower airway inflammation, promote ventilation-perfusion mismatch, and consequently worsen pulmonary hypertension. In addition, infection prevention interventions such as influenza immunization, are also important as infants with BPD and pulmonary hypertension can experience respiratory failure in the setting of acute viral infections.
Pulmonary hypertension-specific medications have emerged for the care of pulmonary arterial hypertension in adults over the past 20 years, and been applied to children. These include three broad classes of medications: [1] prostacylins and prostacyclin derivatives; [2] modulators of the nitric oxide pathway; [3] and inhibitors of endothelin-related vasoconstriction [40] . Pulmonary hypertension-specific medications are used frequently in the BPD population, but overall there is a lack of consensus as to the best practice with these medications.
In the acute setting of a hospitalized neonate, inhaled nitric oxide is often the first-line therapy to improve oxygenation through pulmonary vasodilation, and is the only FDA-approved agent for the management of any form of pulmonary hypertension in children (although not specifically approved in the BPD population) [41] . This medication has the advantage of a rapid onset of significant pulmonary vasodilation without systemic vasodilation, but it is not generally applied over the long-term pulmonary hypertension management. Of the available medications, sildenafil has the most evidence for its use in the BPD population, but most of this evidence is retrospective case reviews [42] . Sildenafil is a phosphodiesterase-5 inhibitor that prevents breakdown of cyclic guanosine monophosphate and, thus, augments the efficacy of endogenous nitric oxide to promote pulmonary vasodilatation. There is evidence that sildenafil improves echocardiographic and clinical parameters of BPD-PH, but there are persistent questions regarding the longterm clinical benefit of the medication. A recent recommendation by the FDA was countered by a published reply written by several pediatric pulmonary hypertension clinicians in North America [43] [44] [45] . Recent dosing recommendations for this medication often focuses on reaching lower-dose target levels (2-3 mg/kg/day frequently divided as a dose given 3-4 times/day), rather than higher doses (up to 8 mg/kg/day) as was originally reported in the literature because of safety concerns [42, 46, 47] .
Interestingly, recent multicenter data report that the median duration of sildenafil therapy in the BPD population is about 50 days, suggesting that longterm exposure is a rare need [48] . This short duration of therapy is in agreement with the natural history of most infants with BPD-PH in which pulmonary hypertension tends to resolve within the first year of life. However, this should not be taken as proof of clinical efficacy. Currently, there is no clear evidence that sildenafil directly enhances lung growth or vascular growth. Clearly, there is urgency surrounding the need for continued research in the field.
For some infants with BPD and pulmonary hypertension, the severity of their pulmonary vascular disease warrants therapy beyond monotherapy with sildenafil. Although endothelin antagonists, such as bosentan, or prostacyclin analogues are sometimes used, efficacy and dosing data in the BPD population are limited [10 && ]. In our experience, escalation of pulmonary hypertension-specific therapy beyond monotherapy should trigger a focused evaluation of comorbid conditions and concurrent therapeutic exposures, and strong consideration for cardiac catheterization prior to addition of another pulmonary hypertension-specific medication.
CONCLUSION
In summary, pulmonary hypertension often complicates BPD, wherein lung growth and alveolarization are compromised by impaired vascular development that decreases pulmonary capillary cross-sectional area and increases pulmonary vascular resistance. Infants with BPD are at increased risk for the development of pulmonary hypertension, and echocardiographic evaluation is essential even as more standardized approaches to interpretation of echocardiophic data are pursued. Treatment entails promoting lung growth, ensuring adequate oxygenation and ventilation, and minimizing secondary insults to the lungs. When pulmonary hypertension-specific therapy is initiated the first-line choice is sildenafil; however, there is a significant need for research to guide dosing and use of this medication. Other pulmonary hypertensionspecific medications are sometimes employed in this population, but there is even less evidence to guide these medications. Although for most infants with BPD and pulmonary hypertension, the natural history is resolution of pulmonary hypertension by the first year of life, the prognosis for children with ongoing pulmonary hypertension is significantly less favorable [5 & ,49] . Future research needs to continue to focus on early identification of these infants, as well as best treatment practices. The retrospective case-series of 42 premature infants from 1998-2006 is one of the initial manuscripts to describe pulmonary hypertension in the setting of a more modern BPD population. This manuscript includes hemodynamic parameters and survival data of the premature infants who developed pulmonary hypertension.
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